Movement Alert｜Gilead Sciences Intraday Rise 3.02% in Regular Trading, DZ Bank Raises Price Target to 191 USD

Market Focus00:12

On November 5, Gilead Sciences rose 3.02% in Regular Trading, trading at $172.385 per share, with turnover of $397 million.

The most direct catalyst in recent market news was DZ Bank raising its price target on Gilead Sciences to $191 from $167, a level above the FactSet-tracked mean target of $172.76, reinforcing expectations for further valuation upside.

That target revision followed a strong quarterly update released on October 30, when Gilead Sciences reported Q3 adjusted EPS of $2.55 on revenue of $8.30 billion, both above market expectations, while product sales guidance for the full year was raised to $31.0 billion to $31.3 billion. In the days after the results, multiple brokers also lifted their targets, adding support to sentiment around the stock.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment